Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Darbepoetin Alpha and Recombinant Human Erythropoietin for Treatment of Anemia in Children With Chronic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 1-18 years.~2. CKD patients stages 3 to 5 (on or not on dialysis).~3. Baseline hemoglobin 9 - 12 g/dL.~4. Subject should have adequate transferrin saturation (≥20%) and serum ferritin (≥100 ng/mL).~5. Stable erythropoietin therapy for 8 weeks ( defined as a ≤25% change in prescribed dose, no change in the route of administration and no more than one missed or withheld dose).~Exclusion Criteria:~1. Subject scheduled for a living-related kidney transplant.~2. Subject with uncontrolled hypertension.~3. HIV positive patient.~4. The patient with known hematologic disease or cause of anemia other than renal disease.~5. Patient with a history of seizure disorder or received antiepileptic medication for a seizure disorder within 6 months prior to enrolment.~6. Hyperparathyroidism (Intact parathyroid hormone more than 1500 pg/ml or biopsy proven marrow fibrosis).~7. Major surgery within 12 weeks.~8. Active inflammatory disease within 8 weeks of randomization requiring immunosuppressive therapy.~9. Clinical evidence of malignancy.~10. Blood transfusion within 8 weeks prior to initiation of therapy.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Erythropoietin (Type: ACTIVE_COMPARATOR): Recombinant Human Erythropoietin
- Darbepoetin alfa (Type: EXPERIMENTAL): Darbepoetin Alpha

Based on this trial design, predict the completion outcome and termination type (if applicable).